KTP 001

Drug Profile

KTP 001

Alternative Names: KTP-001; Recombinant human matrix metalloproteinase - Kaketsuken/Teijin

Latest Information Update: 02 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Yamanashi; Yokohama City Minato Red Cross Hospital
  • Developer Kaketsuken; Teijin Pharma
  • Class Matrix metalloproteinases; Recombinant proteins
  • Mechanism of Action Matrix-metalloproteinase-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Intervertebral disc displacement

Most Recent Events

  • 17 Sep 2015 KTP 001 is still in phase I/II trials for Intervertebral disc displacement in USA
  • 01 Feb 2013 Teijin Pharma initiates enrolment in a phase I/II trial in Intervertebral disc displacement in USA (NCT01978912)
  • 29 Oct 2012 KTP 001 is available for licensing in World (excluding Japan) as of 29 Oct 2012. http://www.teijin-pharma.co.jp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top